By Chris Wack
Shares of BioXcel Therapeutics rose after the company said it has reached 33% enrollment in a trial of a treatment for agitation associated with bipolar disorders or schizophrenia.
The biopharmaceutical company's stock was up 13%, to $3.10, midday Friday. The shares hit its 52-week low of $1.72 on Feb. 27, and are down 94% in the past 12 months.
BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential supplemental new drug application submission to expand the label of the Food and Drug Administration-approved Igalmi sublingual film.
The New Haven, Conn., company's at-home trial currently has 67 patients enrolled, with 23 clinical trial sites open.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 07, 2025 14:09 ET (19:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.